NCT03071406 2026-03-11
Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
Clinical Trials
39 trialsNCT06981325 2026-03-11
CEMI-first
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Recruiting
NCT07455331 2026-03-06
LANCE
Jules Bordet Institute
Phase 2 Not yet recruiting
NCT04526730 2026-02-20
Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT07288073 2026-02-13
TIL Therapy in cSCC and MCC
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT03944941 2026-02-05
Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Active not recruiting
NCT07387198 2026-02-04
NeoMatryx
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Not yet recruiting
NCT04305145 2026-01-29
Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT04562129 2026-01-29
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT05779423 2026-01-06
Cryoablation+Ipilimumab+Nivolumab in Melanoma
Massachusetts General Hospital
Phase 2 Recruiting
NCT03534947 2025-12-16
SONIB
Melanoma Institute Australia
Phase 2 Completed
NCT04996823 2025-12-04
Axitinib + Ipilimumab in Advanced Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT04869137 2025-10-31
Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT04273061 2025-09-22
CAPTIV-8
British Columbia Cancer Agency
Phase 2 Recruiting
NCT05574101 2025-08-08
A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04329221 2025-05-07
Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients
Massachusetts General Hospital
Phase 2 Withdrawn
NCT04642287 2025-05-07
Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant Recipients
Massachusetts General Hospital
Phase 2 Withdrawn
NCT06159842 2025-02-12
Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (isSCC)
The Center for Clinical and Cosmetic Research
Phase 2 Completed
NCT03714828 2024-10-09
Study of TVEC in Patients With Cutaneous Squamous Cell Cancer
University of Arizona
Phase 2 Completed
NCT06577311 2024-08-29
Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (SCCis)
The Center for Clinical and Cosmetic Research
Phase 2 Recruiting
NCT03012581 2024-02-28
AcSé
UNICANCER
Phase 2 Completed
NCT02036476 2023-05-09
Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT02218164 2022-10-07
Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT01835626 2021-05-03
Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma
University of California, San Francisco
Phase 2 Completed
NCT03972046 2020-10-19
Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma
TriHealth Inc.
Phase 2 Withdrawn
NCT02347813 2020-06-23
Preventing Squamous Cell Skin Cancer
University of Rochester
Phase 2 Completed
NCT02705352 2020-03-09
5-fluorouracil Versus Placebo in Periocular Full Thickness Skin Grafts
Massachusetts Eye and Ear Infirmary
Phase 2 Completed
NCT00204789 2019-12-16
Difluoromethylornithine (DFMO) Chemoprevention of Skin Cancer in Organ Transplant Recipients
University of Wisconsin, Madison
Phase 2 Completed
NCT00254397 2019-10-16
Melanoma Vaccine With Peptides and Leuprolide
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02303041 2019-01-29
Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma
Stanford University
Phase 2 Terminated
NCT03666325 2018-09-11
I-Tackle
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
NCT01823679 2018-04-12
Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin
Stanford University
Phase 2 Terminated
NCT02061007 2016-05-09
Biomarker Correlates of Hypoxia in Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Withdrawn
NCT00588341 2016-02-01
Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01474551 2015-11-18
Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT00885534 2015-05-06
Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00054691 2015-03-13
ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00002506 2011-05-12
Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer
Hoag Memorial Hospital Presbyterian
Phase 2 Completed
NCT00586040 2009-04-10
PTB
Massachusetts General Hospital
Phase 2 Completed